MCID: APP009
MIFTS: 44

Appendix Adenocarcinoma

Categories: Cancer diseases, Endocrine diseases, Gastrointestinal diseases, Rare diseases

Aliases & Classifications for Appendix Adenocarcinoma

MalaCards integrated aliases for Appendix Adenocarcinoma:

Name: Appendix Adenocarcinoma 12 15 17
Mucinous Adenocarcinoma 52 71
Cystadenocarcinoma 52 71
Adenocarcinoma of the Appendix 52
Colonic Type Adenocarcinoma 52
Appendiceal Adenocarcinoma 12
Nonmucinous Adenocarcinoma 52
Adenocarcinoma of Appendix 71

Classifications:



External Ids:

Disease Ontology 12 DOID:3608
NCIt 49 C7718
SNOMED-CT 67 413445002
UMLS 71 C0007130 C0010631 C0238003

Summaries for Appendix Adenocarcinoma

NIH Rare Diseases : 52 Cancer of the appendix is very rare and is typically found incidentally during appendectomies, in about 1% of the cases. According to a report published by the National Cancer Institute, using the Surveillance, Epidemiology, and End Results (SEER) database, appendix cancer account for about 0.4% of gastrointestinal tumors . There are several subytpes. The most common is the carcinoid type (66% of the total), with cyst-adenocarcinoma accounting for 20% and adenocarcinoma accounting for 10%. Then there are the rare forms of cancers which include adenocarcinoid, signet ring, non-Hodgkin's lymphoma, ganglioneuroma, and pheochromocytoma. Benign primary tumors are mainly "mucinous epithelial neoplasms", also called adenomas, cystadenoma, and benign neoplastic mucocele. Adenocarcinoma of the appendix is a epithelial cancer of the appendix. The term 'epithelium' refers to cells that line hollow organs and glands and those that make up the outer surface of the body. Epithelial cells help to protect or enclose organs. Some produce mucus or other secretions. Types of adenocarcinoma of the appendix include mucinous adenocarcinoma, non-mucinous adenocarcinoma, and signet cell carcinoma of the appendix (which is the rarest, involving only 4% of all the subtypes of appendix cancer).

MalaCards based summary : Appendix Adenocarcinoma, also known as mucinous adenocarcinoma, is related to papillary cystadenocarcinoma and acinar cell cystadenocarcinoma. An important gene associated with Appendix Adenocarcinoma is CDX2 (Caudal Type Homeobox 2), and among its related pathways/superpathways are Relaxin signaling pathway and Cell surface interactions at the vascular wall. The drugs Cobalt and Lenograstim have been mentioned in the context of this disorder. Affiliated tissues include appendix, colon and lung.

Disease Ontology : 12 An appendix carcinoma that derives from epithelial cells of glandular origin.

Related Diseases for Appendix Adenocarcinoma

Diseases related to Appendix Adenocarcinoma via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 736)
# Related Disease Score Top Affiliating Genes
1 papillary cystadenocarcinoma 34.1 KRT7 KRT20
2 acinar cell cystadenocarcinoma 33.9 SYP CHGA
3 cervical adenoma malignum 33.4 KRT7 CDX2
4 bile duct cystadenocarcinoma 33.1 KRT7 KRT20 CEACAM5
5 mucinous stomach adenocarcinoma 33.0 KRT7 CDX2
6 ovarian mucinous adenocarcinoma 32.9 KRT7 KRT20 CEACAM5 CDX2
7 mucinous adenocarcinoma 32.6 KRT7 KRT20 KRAS CEACAM5 CDX2
8 pancreatic serous cystadenocarcinoma 32.4 SYP KRT7 KRT20 CHGA CEACAM5
9 ovarian serous cystadenocarcinoma 32.2 SYP KRAS HRAS GNAS CEACAM5
10 pseudomyxoma peritonei 31.3 KRT7 KRT20 KRAS CEACAM5 CDX2
11 anus adenocarcinoma 30.8 KRT7 CDX2
12 anal canal adenocarcinoma 30.8 KRT7 CDX2
13 papillary serous adenocarcinoma 30.7 KRT7 KRT20 KRAS CEACAM5
14 mucinous lung adenocarcinoma 30.6 KRAS HRAS
15 adenosquamous colon carcinoma 30.4 KRT7 CDX2
16 ovarian germ cell teratoma 30.3 SYP KRT7
17 goblet cell carcinoid 30.3 KRT20 CHGA
18 ovarian cystadenoma 30.3 KRT7 CEACAM5
19 epididymis adenocarcinoma 30.3 KRT7 CDX2
20 microcystic adenoma 30.3 SYP CHGA
21 urachal adenocarcinoma 30.2 KRAS GNAS CEACAM5
22 acinar cell carcinoma 30.2 SYP KRT7 CHGA
23 serous cystadenocarcinoma 30.2 KRT7 KRAS HRAS
24 ovarian brenner tumor 30.2 KRT7 KRT20
25 bladder adenocarcinoma 30.2 KRT7 KRT20 CDX2
26 solid adenocarcinoma with mucin production 30.2 KRT7 CHGA
27 struma ovarii 30.2 KRT7 KRAS
28 carcinoid tumors, intestinal 30.1 SYP CHGA
29 pulmonary adenocarcinoma in situ 30.1 KRAS HRAS
30 warthin tumor 30.1 KRT7 CEACAM5
31 intrahepatic cholangiocarcinoma 30.1 KRT7 KRT20 KRAS CDX2
32 meckel diverticulum 30.0 CHGA CDX2
33 eyelid carcinoma 30.0 KRT7 KRT20
34 cystadenocarcinoma 30.0 KRT7 HRAS CEACAM5
35 benign mesothelioma 30.0 KRT7 CEACAM5
36 endosalpingiosis 29.9 KRT7 KRAS HRAS
37 hemangioma 29.8 SYP KRT7 KRAS CHGA
38 sclerosing hemangioma 29.8 SYP KRT7 CHGA
39 biliary papillomatosis 29.8 KRT7 CEACAM5
40 cavernous hemangioma 29.7 SYP KRT7 KRT20
41 klatskin's tumor 29.7 KRT7 CEACAM5
42 transitional cell carcinoma 29.7 KRT7 KRT20 HRAS
43 papilloma 29.7 KRT7 KRT20 KRAS
44 pancreatic cystadenoma 29.6 SYP CHGA CEACAM5
45 spindle cell carcinoma 29.6 SYP KRT7 HRAS CHGA
46 jejunal neoplasm 29.5 SYP KRT7 KRT20
47 intestinal obstruction 29.5 KRT7 KRT20 CEACAM5 CDX2
48 gastrointestinal carcinoma 29.5 KRT20 CEACAM5 CDX2
49 polycystic liver disease 1 with or without kidney cysts 29.5 KRT7 KRT20 CEACAM5
50 large cell neuroendocrine carcinoma 29.4 SYP KRT7 KRT20 CHGA

Graphical network of the top 20 diseases related to Appendix Adenocarcinoma:



Diseases related to Appendix Adenocarcinoma

Symptoms & Phenotypes for Appendix Adenocarcinoma

Drugs & Therapeutics for Appendix Adenocarcinoma

Drugs for Appendix Adenocarcinoma (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 221)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Cobalt Approved, Experimental Phase 3 7440-48-4 104729
2
Lenograstim Approved, Investigational Phase 3 135968-09-1
3
Everolimus Approved Phase 2, Phase 3 159351-69-6 70789204 6442177
4
Olaparib Approved Phase 2, Phase 3 763113-22-0 23725625
5
Docetaxel Approved, Investigational Phase 3 114977-28-5 148124
6
Letrozole Approved, Investigational Phase 2, Phase 3 112809-51-5 3902
7
Metformin Approved Phase 2, Phase 3 657-24-9 14219 4091
8
Trametinib Approved Phase 2, Phase 3 871700-17-3 11707110
9
Sodium citrate Approved, Investigational Phase 2, Phase 3 68-04-2
10
Dimethyl sulfoxide Approved, Vet_approved Phase 2, Phase 3 67-68-5 679
11
Tamoxifen Approved Phase 2, Phase 3 10540-29-1 2733526
12
Cisplatin Approved Phase 2, Phase 3 15663-27-1 2767 441203 84093
13
Topotecan Approved, Investigational Phase 2, Phase 3 123948-87-8, 119413-54-6 60700
14
Etoposide Approved Phase 2, Phase 3 33419-42-0 36462
15
Gemcitabine Approved Phase 2, Phase 3 95058-81-4 60750
16
Paclitaxel Approved, Vet_approved Phase 3 33069-62-4 36314
17
Carboplatin Approved Phase 3 41575-94-4 10339178 38904 498142
18
Bevacizumab Approved, Investigational Phase 2, Phase 3 216974-75-3
19
Pembrolizumab Approved Phase 3 1374853-91-4
20
Atezolizumab Approved, Investigational Phase 2, Phase 3 1380723-44-3
21
Doxorubicin Approved, Investigational Phase 2, Phase 3 23214-92-8 31703
22
Cyclophosphamide Approved, Investigational Phase 3 50-18-0, 6055-19-2 2907
23
Mitoxantrone Approved, Investigational Phase 3 65271-80-9 4212
24
Glutamic acid Approved, Nutraceutical Phase 3 56-86-0 33032
25
Citric acid Approved, Nutraceutical, Vet_approved Phase 2, Phase 3 77-92-9 311
26 Edrecolomab Experimental, Investigational Phase 3 156586-89-9
27
Camptothecin Experimental Phase 3 7689-03-4
28
Cediranib Investigational Phase 2, Phase 3 288383-20-0 9933475
29
Maleic acid Experimental, Investigational Phase 2, Phase 3 110-17-8, 110-16-7 444972
30 Paclitaxel poliglumex Experimental, Investigational Phase 3 263351-82-2
31 Mitomycins Phase 3
32 Formyltetrahydrofolates Phase 3
33 Tetrahydrofolates Phase 3
34 Adjuvants, Immunologic Phase 3
35 Poly(ADP-ribose) Polymerase Inhibitors Phase 2, Phase 3
36 Carotenoids Phase 3
37 Antimetabolites Phase 3
38 topoisomerase I inhibitors Phase 2, Phase 3
39 Hormones Phase 2, Phase 3
40 Hematinics Phase 3
41 Hormone Antagonists Phase 2, Phase 3
42 Estrogen Antagonists Phase 2, Phase 3
43 Estrogen Receptor Antagonists Phase 2, Phase 3
44 Estrogens Phase 2, Phase 3
45 Aromatase Inhibitors Phase 2, Phase 3
46 Antineoplastic Agents, Hormonal Phase 2, Phase 3
47 Hypoglycemic Agents Phase 2, Phase 3
48 Estrogen Receptor Modulators Phase 2, Phase 3
49 taxane Phase 3
50 Citrate Phase 2, Phase 3

Interventional clinical trials:

(show top 50) (show all 224)
# Name Status NCT ID Phase Drugs
1 RANDOMIZED TRIAL OF CONCOMITANT PREOPERATIVE RADIO-CHEMOTHERAPY WITH OR WITHOUT POSTOPERATIVE CHEMOTHERAPY IN LOCALLY ADVANCED RECTAL CARCINOMA Unknown status NCT00002896 Phase 3 chemotherapy;fluorouracil;leucovorin calcium
2 Pilot / Phase III Randomized Trial Comparing Standard Systemic Therapy to Cytoreduction + Hyperthermic Intraperitoneal Mitomycin C + Standard Systemic Therapy in Patients With Limited Peritoneal Dissemination of Colon Adenocarcinoma Unknown status NCT01167725 Phase 3 FOLFIRI regimen;FOLFOX regimen;capecitabine;fluorouracil;irinotecan hydrochloride;leucovorin calcium;mitomycin C;oxaliplatin
3 A Randomized Phase III Equivalence Trial of Irinotecan (CPT-11) Versus Oxaliplatin (OXAL)/5-Fluorouracil (5-FU)/Leucovorin (CF) in Patients With Advanced Colorectal Carcinoma Previously Treated With 5-FU Completed NCT00005036 Phase 3 irinotecan hydrochloride;oxaliplatin;leucovorin calcium;fluorouracil
4 Phase III Randomized Study of Adjuvant Immunotherapy With Monoclonal Antibody 17-1A Versus No Adjuvant Therapy Following Resection for State II (Modified Astler-Coller B2) Adenocarcinoma of the Colon Completed NCT00002968 Phase 3
5 Intergroup Randomized Phase III Study of Postoperative Irinotecan, 5-Fluorouracil and Leucovorin vs. Oxaliplatin, 5-Fluorouracil and Leucovorin vs. 5-Fluorouracil and Leucovorin for Patients With Stage II or III Rectal Cancer Receiving Either Preoperative Radiation and 5-Fluorouracil or Postoperative Radiation and 5-Fluorouracil Completed NCT00068692 Phase 3 Fluorouracil;Leucovorin Calcium;Oxaliplatin;Irinotecan
6 Pan-European Trials in Adjuvant Colon Cancer (PETACC-2): Randomized Phase III Intergroup Trial of High-Dose Infusional 5-FU (+ or - Folinic Acid) Versus Standard Bolus 5-FU/Folinic Acid Completed NCT00004150 Phase 3 fluorouracil;leucovorin calcium
7 A PHASE III RANDOMIZED STUDY OF CISPLATIN (NSC #119875) AND TAXOL (PACLITAXEL) (NSC #125973) WITH INTERVAL SECONDARY CYTOREDUCTION VERSUS CISPLATIN AND PACLITAXEL IN PATIENTS WITH SUBOPTIMAL STAGE III & IV EPITHELIAL OVARIAN CARCINOMA Completed NCT00002568 Phase 3 cisplatin;paclitaxel
8 CRAD001X2401: Treatment Plan for an Individual Patient With Recurrent Uterine Papillary Serous Carcinoma (UPSC) With PIK3CA Gene Mutation Completed NCT03285802 Phase 2, Phase 3 Letrozole;Everolimus
9 A Randomized Phase III Trial of IV Carboplatin (AUC 6) and Paclitaxel 175 mg/m2 Q 21 Days x 3 Courses Plus Low Dose Paclitaxel 40 mg/m2/wk Versus IV Carboplatin (AUC 6) and Paclitaxel 175 mg/m2 Q 21 Days x 3 Courses Plus Observation in Patients With Early Stage Ovarian Carcinoma Completed NCT00003644 Phase 3 carboplatin;paclitaxel
10 A Phase III Randomized Trial of Cisplatin (NSC #119875) With Paclitaxel (NSC #125973) Administered by Either 24 Hour Infusion or 96 Hour Infusion in Patients With Selected Stage III and Stage IV Epithelial Ovarian Cancer and Primary Peritoneal Carcinoma Completed NCT00002717 Phase 3 cisplatin;paclitaxel
11 A Phase III Randomized Trial of Intravenous Paclitaxel and Cisplatin Versus Intravenous Paclitaxel, Intraperitoneal Cisplatin and Intraperitoneal Paclitaxel in Patients With Optimal Stage III Epithelial Ovarian Carcinoma or Primary Peritoneal Carcinoma Completed NCT00003322 Phase 3 cisplatin;paclitaxel
12 ICON7 - A Randomised, Two-Arm, Multi-Centre Gynaecologic Cancer InterGroup Trial of Adding Bevacizumab to Standard Chemotherapy (Carboplatin and Paclitaxel) in Patients With Epithelial Ovarian Cancer Completed NCT00483782 Phase 3 carboplatin;paclitaxel
13 A Randomized Phase III Study of Tumor Volume Directed Pelvic Plus or Minus Para-Aortic Irradiation Followed by Cisplatin and Doxorubicin or Cisplatin, Doxorubicin and Paclitaxel for Advanced Endometrial Carcinoma Completed NCT00006011 Phase 3 Doxorubicin Hydrochloride;Cisplatin;Paclitaxel
14 A Phase III Trial of Carboplatin and Paclitaxel Plus Placebo Versus Carboplatin and Paclitaxel Plus Concurrent Bevacizumab (NSC # 704865) Followed by Placebo, Versus Carboplatin and Paclitaxel Plus Concurrent and Extended Bevacizumab, in Women With Newly Diagnosed, Previously Untreated, Stage III or IV Epithelial Ovarian, Primary Peritoneal or Fallopian Tube Cancer Completed NCT00262847 Phase 3 Carboplatin;Paclitaxel
15 Randomized Phase III Trial of the Need for Adjuvant Chemotherapy in Stage I Epithelial Ovarian Cancer After Comprehensive Staging Surgery Recruiting NCT04063527 Phase 3 adjuvant chemotherapy
16 Randomized Phase III Trial of Cisplatin and Tumor Volume Directed Irradiation Followed by Carboplatin and Paclitaxel Vs. Sandwich Therapy of Carboplatin and Paclitaxel Followed by Tumor Volume Directed Irradiation Then Further Carboplatin and Paclitaxel Recruiting NCT02501954 Phase 3 Cisplatin;Carboplatin;Paclitaxel
17 Short Course Adjuvant Vaginal Cuff Brachytherapy (VCB) in Early Endometrial Cancer Compared to Standard of Care (SAVE) Recruiting NCT03422198 Phase 3
18 A Randomized Phase III, Two-Arm Trial of Paclitaxel/Carboplatin/Maintenance Letrozole Versus Letrozole Monotherapy in Patients With Stage II-IV, Primary Low-Grade Serous Carcinoma of the Ovary or Peritoneum Recruiting NCT04095364 Phase 3 Carboplatin;Letrozole;Paclitaxel
19 Can Diet and Physical Activity Modulate Ovarian, Fallopian Tube and Primary Peritoneal Cancer Progression-Free Survival? Recruiting NCT00719303 Phase 3
20 A Randomized Phase II/III Study of the Combination of Cediranib and Olaparib Compared to Cediranib or Olaparib Alone, or Standard of Care Chemotherapy in Women With Recurrent Platinum-Resistant or -Refractory Ovarian, Fallopian Tube, or Primary Peritoneal Cancer (COCOS) Recruiting NCT02502266 Phase 2, Phase 3 Cediranib;Cediranib Maleate;Olaparib;Paclitaxel;Pegylated Liposomal Doxorubicin Hydrochloride;Topotecan;Topotecan Hydrochloride
21 A GCIG Intergroup Multicenter Phase III Trial of Open Label Carboplatin and Paclitaxel +/- NCI-Supplied Agent: Bevacizumab (NSC #704865) Compared With Oxaliplatin and Capecitabine +/- Bevacizumab as First Line Chemotherapy in Patients With Mucinous Epithelial Ovarian or Fallopian Tube Cancer (MEOC) Active, not recruiting NCT01081262 Phase 3 Capecitabine;Carboplatin;Oxaliplatin;Paclitaxel
22 A Randomized Phase III Study Comparing 5-FU, Leucovorin and Oxaliplatin Versus 5-FU, Leucovorin, Oxaliplatin and Bevacizumab in Patients With Stage II Colon Cancer at High Risk for Recurrence to Determine Prospectively the Prognostic Value of Molecular Markers Active, not recruiting NCT00217737 Phase 3 Fluorouracil;Leucovorin Calcium;Oxaliplatin
23 A Randomized Phase III Trial of Maintenance Chemotherapy Comparing 12, Monthly Cycles of Single Agent Paclitaxel or CT-2103 Versus No Treatment Until Documented Relapse in Women With Advanced Ovarian, Primary Peritoneal or Fallopian Tube Cancer Who Achieve a Complete Clinical Response to Primary Platinum/Taxane Chemotherapy Active, not recruiting NCT00108745 Phase 3 Paclitaxel;Paclitaxel Poliglumex
24 A Phase III Clinical Trial of Bevacizumab With IV Versus IP Chemotherapy in Ovarian, Fallopian Tube and Primary Peritoneal Carcinoma Active, not recruiting NCT00951496 Phase 3 Carboplatin;Carboplatin;Cisplatin;Paclitaxel;Paclitaxel
25 A Phase III Randomized Controlled Clinical Trial of Carboplatin and Paclitaxel (or Gemcitabine) Alone or in Combination With Bevacizumab (NSC #704865) Followed by Bevacizumab and Secondary Cytoreductive Surgery in Platinum-Sensitive, Recurrent Ovarian, Peritoneal Primary and Fallopian Tube Cancer. NCI-Supplied Agents: Bevacizumab (NSC #704865) Active, not recruiting NCT00565851 Phase 3 Carboplatin;Docetaxel;Gemcitabine Hydrochloride;Paclitaxel
26 GOG-0262: A Phase III Trial of Every-3-Weeks Paclitaxel Versus Dose Dense Weekly Paclitaxel in Combination With Carboplatin With or Without Concurrent and Consolidation Bevacizumab (NSC #704865) in the Treatment of Primary Stage II, III or IV Epithelial Ovarian, Peritoneal or Fallopian Tube Cancer and ACRIN 6695: Perfusion CT Imaging to Evaluate Treatment Response in Patients Participating in GOG-0262 Active, not recruiting NCT01167712 Phase 3 Carboplatin;Paclitaxel
27 A Phase III Trial of Pelvic Radiation Therapy Versus Vaginal Cuff Brachytherapy Followed by Paclitaxel/Carboplatin Chemotherapy in Patients With High Risk, Early Stage Endometrial Carcinoma Active, not recruiting NCT00807768 Phase 3 Carboplatin;Paclitaxel
28 A Randomized Phase III Trial of Cisplatin and Tumor Volume Directed Irradiation Followed by Carboplatin and Paclitaxel vs. Carboplatin and Paclitaxel for Optimally Debulked, Advanced Endometrial Carcinoma Active, not recruiting NCT00942357 Phase 3 Carboplatin;Cisplatin;Paclitaxel
29 A Randomized Phase II/III Study to Assess the Efficacy of Trametinib (GSK 1120212) in Patients With Recurrent or Progressive Low-Grade Serous Ovarian Cancer or Peritoneal Cancer Active, not recruiting NCT02101788 Phase 2, Phase 3 Letrozole;Paclitaxel;Pegylated Liposomal Doxorubicin Hydrochloride;Tamoxifen;Tamoxifen Citrate;Topotecan;Topotecan Hydrochloride;Trametinib;Trametinib Dimethyl Sulfoxide
30 A Randomized Phase II/III Study of Paclitaxel/Carboplatin/Metformin (NSC#91485) Versus Paclitaxel/Carboplatin/Placebo as Initial Therapy for Measurable Stage III or IVA, Stage IVB, or Recurrent Endometrial Cancer Active, not recruiting NCT02065687 Phase 2, Phase 3 Carboplatin;Metformin Hydrochloride;Paclitaxel
31 Randomized Phase II/III Trial to Assess the Efficacy of Platinum-based Chemotherapy vs Standard Non-platinum Therapy in Patients With Platinum-resistant Recurrent Ovarian Cancer (ROC) Not yet recruiting NCT04055038 Phase 2, Phase 3 Platinum-Based Drug;Conventional chemotherapy
32 A Phase III Randomized, Placebo-Controlled Study of Pembrolizumab (MK-3475, NSC #776864) in Addition to Paclitaxel and Carboplatin for Measurable Stage III or IVA, Stage IVB or Recurrent Endometrial Cancer Suspended NCT03914612 Phase 3 Carboplatin;Paclitaxel
33 A Randomized, Phase II/III Study of Pegylated Liposomal Doxorubicin and CTEP-Supplied Atezolizumab Versus Pegylated Liposomal Doxorubicin/Bevacizumab and CTEP-Supplied Atezolizumab Versus Pegylated Liposomal Doxorubicin/Bevacizumab in Platinum Resistant Ovarian Cancer Suspended NCT02839707 Phase 2, Phase 3 Atezolizumab;Pegylated Liposomal Doxorubicin Hydrochloride
34 A Phase II/III Trial of Chemotherapy Alone Versus Chemotherapy Plus SCH 58500 in Newly Diagnosed Stage III Ovarian and Primary Peritoneal Cancer Patients With Greater Than or Equal to 0.5 cm and Less Than or Equal to 2 cm Residual Disease Following Surgery Terminated NCT00003880 Phase 2, Phase 3 carboplatin;paclitaxel
35 A RANDOMIZED, CONTROLLED TRIAL OF SALVAGE THERAPY WITH PACLITAXEL AND CARBOPLATIN VERSU SALVAGE THERAPY WITH STEM CELL SUPPORTED HIGH-DOSE CARBOPLATIN, MITOXANTRONE AND CYCLOPHOSPHAMIDE IN PATIENTS WITH PERSISTENT LOW VOLUME OVARIAN CANCER AND RESPONSE TO PRIMARY THERAPY Terminated NCT00002819 Phase 3 carboplatin;cyclophosphamide;mitoxantrone hydrochloride;paclitaxel
36 A Randomized, Double-Blinded, Placebo Controlled Phase III Trial Using Acetyl-L-Carnitine(ALC)(NSC# 747431) for the Prevention of Chemotherapy-Induced Peripheral Neuropathy in Patients With Recurrent Ovarian, Primary Peritoneal or Fallopian Tube Cancer Withdrawn NCT01492920 Phase 3
37 A Phase II Trial Of IM862 Combined With Paclitaxel And Carboplatin In Newly Diagnosed Advanced Epithelial Ovarian Or Primary Peritoneal Carcinoma Followed By IM862 Consolidation Therapy Unknown status NCT00017303 Phase 2 carboplatin;oglufanide disodium;paclitaxel
38 A Phase 2 Study of MK-2206 in Previously Treated Metastatic Colorectal Cancer Patients Enriched for PTEN Loss and PIK3CA Mutation Completed NCT01802320 Phase 2 Akt Inhibitor MK2206
39 Phase II Trial of Continuous Hyperthermic Peritoneal Perfusion (CHPP) With Cisplatin Plus Early Postoperative Intraperitoneal Paclitaxel and 5-Fluorouracil for Peritoneal Carcinomatosis Completed NCT00004547 Phase 2 Postoperative dwell with paclitaxel and 5-FU
40 Phase II Trial of Surgical Resection and Heated Intraperitoneal Peritoneal Chemotherapy (HIPEC) for Adrenocortical Carcinoma Completed NCT01833832 Phase 2 Cisplatin;sodium thiosulfate
41 A Phase II Study of TLK 286 in Platinum Resistant Advanced Epithelial Ovarian Cancer Completed NCT00022347 Phase 2 canfosfamide hydrochloride
42 LAPAROSCOPIC STAGING IN PATIENTS WITH INCOMPLETELY STAGED CANCERS OF THE OVARY Completed NCT00002538 Phase 2
43 A Phase II Evaluation of Belinostat (NSC #726630) and Carboplatin (NSC #241240) in the Treatment of Recurrent or Persistent Platinum-Resistant Ovarian, Fallopian Tube, or Primary Peritoneal Cancer Completed NCT00993616 Phase 2 belinostat;carboplatin
44 A Phase II Evaluation of BIBF 1120 in the Treatment of Recurrent or Persistent Endometrial Carcinoma Completed NCT01225887 Phase 2 Nintedanib
45 A Phase II Trial Using Multiple Cycles of High Dose Sequential Carboplatin, Paclitaxel and Topotecan With Peripheral Blood Stem Cell (PBSC) Support as Initial Chemotherapy in Patients With Suboptimally Debulked Stage III or IV Ovarian, Fallopian Tube or Primary Peritoneal Carcinoma Completed NCT00003944 Phase 2 carboplatin;cyclophosphamide;paclitaxel;topotecan hydrochloride
46 A Phase 2 Trial of Letrozole and Everolimus in Relapsed Hormone Receptor Positive Ovarian, Fallopian Tube or Primary Peritoneal Carcinomas Completed NCT02283658 Phase 2 Everolimus;Letrozole
47 Phase II Evaluation Of Neoadjuvant Chemotherapy, Interval Debulking Followed By Intraperitoneal Chemotherapy In Women With Stage III And IV Epithelial Ovarian Cancer, Fallopian Tube Cancer Or Primary Peritoneal Cancer Completed NCT00008138 Phase 2 carboplatin;paclitaxel
48 Phase II Study of Erlotinib Plus Carboplatin and Paclitaxel in Patients With Ovarian, Fallopian Tube, or Primary Peritoneal Carcinoma Completed NCT00059787 Phase 2 paclitaxel;carboplatin;erlotinib
49 A Phase II Evaluation of a Urokinase-Derived Peptide (A6) in the Treatment of Persistent or Recurrent Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Carcinoma Completed NCT00939809 Phase 2
50 A Phase I-II Study of OSI-774 (Tarceva, Erlotinib) With Docetaxel/Carboplatin Followed by Maintenance Therapy With Tarceva as Treatment for Newly Diagnosed Stage III/IV Epithelial Ovarian Cancer, Primary Peritoneal or Fallopian Tube Cancer Completed NCT00217529 Phase 1, Phase 2 carboplatin;docetaxel;erlotinib hydrochloride

Search NIH Clinical Center for Appendix Adenocarcinoma

Genetic Tests for Appendix Adenocarcinoma

Anatomical Context for Appendix Adenocarcinoma

MalaCards organs/tissues related to Appendix Adenocarcinoma:

40
Appendix, Colon, Lung, Ovary, Prostate, Breast, Cervix

Publications for Appendix Adenocarcinoma

Articles related to Appendix Adenocarcinoma:

(show top 50) (show all 2128)
# Title Authors PMID Year
1
Colonoscopic feature of primary adenocarcinoma of the appendix:. 52
18277025 2008
2
Mucinous adenocarcinoma of the appendix invading the urinary bladder. 61
32322517 2020
3
Clinicopathological and mutational differences between tumors with multiple metastases and single lung metastasis in colorectal cancer. 61
32565980 2020
4
Mucinous adenocarcinoma is a pharmacogenomically distinct subtype of colorectal cancer. 61
31819162 2020
5
Predictive Impact of Mucinous Tumors on the Clinical Outcome in Patients with Poorly Differentiated, Stage II Colon Cancer: A TOSCA Subgroup Analysis. 61
31943506 2020
6
[The clinical characteristics and surgical management of ciliated muconodular papillary tumor]. 61
32575946 2020
7
MUC5AC enhances tumor heterogeneity in lung adenocarcinoma with mucin production and is associated with poor prognosis. 61
32083303 2020
8
Molecular Genetic Features of Primary Nonurachal Enteric-type Adenocarcinoma, Urachal Adenocarcinoma, Mucinous Adenocarcinoma, and Intestinal Metaplasia/Adenoma: Review of the Literature and Next-generation Sequencing Study. 61
32520749 2020
9
Impact of Referral Center Pathology Review on Diagnosis and Management of Patients With Appendiceal Neoplasms. 61
31714810 2020
10
Incidental Finding of Primary Mucinous Adenocarcinoma of Gall Bladder: a Histopathological Diagnosis. 61
32529395 2020
11
Prognostic Impact of Histopathologic Features in Pulmonary Invasive Mucinous Adenocarcinomas. 61
32215558 2020
12
Acinar with ductal and mucinous adenocarcinoma of prostate cancer complicated with lung metastasis: a case report and literature review. 61
32576002 2020
13
Right Lower Lobectomy for an Aberrant Mediastinal Inferior Lobar Artery. 61
31786288 2020
14
Double small bowel cancers leading to the diagnosis of Lynch syndrome with germline MSH6 mutation in an elderly patient. 61
32519314 2020
15
Relationships and Qualitative Evaluation Between Diffusion-Weighted Imaging and Pathologic Findings of Resected Lung Cancers. 61
32397172 2020
16
Gastric-type gene expression and phenotype in non-terminal respiratory unit type adenocarcinoma of the lung with invasive mucinous adenocarcinoma morphology. 61
31985086 2020
17
[Clinicopathological and genetic characteristics of lung cancer in the lungs of explanted from lung transplant recipients]. 61
32392931 2020
18
Leukocyte immunoglobulin-like receptor subfamily B member 1 potentially acts as a diagnostic and prognostic target in certain subtypes of adenocarcinoma. 61
32534335 2020
19
Colorectal carcinomas with mucinous differentiation are associated with high frequent mutation of KRAS or BRAF mutations, irrespective of quantity of mucinous component. 61
32384877 2020
20
Prognostic impact of mucin spread, tumor cell spread, and invasive size in invasive mucinous adenocarcinoma of the lung. 61
32512273 2020
21
Optimal method for measuring invasive size that predicts survival in invasive mucinous adenocarcinoma of the lung. 61
32088782 2020
22
Isolated urethral metastasis from appendiceal mucinous adenocarcinoma. 61
32526660 2020
23
Adenocarcinoma of the lung: from BAC to the future. 61
32430670 2020
24
Risk factors and predictors of lymph nodes metastasis and distant metastasis in newly diagnosed T1 colorectal cancer. 61
32469151 2020
25
RAS/RAF mutations and their associations with epigenetic alterations for distinct pathways in Vietnamese colorectal cancer. 61
32089414 2020
26
Expanding the indication of endoscopic submucosal dissection for undifferentiated early gastric cancer is safe or not? 61
31706922 2020
27
A patient with colitis-associated cancer who developed clinically manifest Crohn's disease only after surgery. 61
32277311 2020
28
Endocrine mucin-producing sweat gland carcinoma - newly described skin appendageal tumours. 61
32342939 2020
29
Primary low-grade mucinous adenocarcinoma spleen resulting in Pseudomyxoma peritonei: A case report. 61
32317535 2020
30
An inflammation index-based prediction of treatment response to neoadjuvant chemoradiotherapy for rectal mucinous adenocarcinoma. 61
32274615 2020
31
Diffusion-weighted magnetic resonance imaging of mucin pools in locally advanced rectal mucinous adenocarcinoma predicts tumor response to neoadjuvant therapy. 61
32092684 2020
32
Primary mucinous adenocarcinoma of the renal pelvis misdiagnosed as calculous pyonephrosis: a case report and literature review. 61
32420184 2020
33
Management and prognostic prediction of appendiceal mucinous adenocarcinoma with peritoneal metastasis: a single center study in China. 61
32252683 2020
34
[Ovarian metastases of pancreatic ductal adenocarcinomas: the clinicopathological characteristics and outcomes of 10 cases]. 61
32375450 2020
35
Mucinous Cell Clusters in Infantile Congenital Pulmonary Airway Malformations Mimic Adult Mucinous Adenocarcinoma But Are Not Associated With Poor Outcomes When Appropriately Resected. 61
32349050 2020
36
Impact of cytoreductive surgery on outcomes of metastatic appendiceal carcinoma: a real-world, population-based study. 61
32253936 2020
37
Clinicopathological characteristics and prognosis of colorectal mucinous adenocarcinoma and nonmucinous adenocarcinoma: a surveillance, epidemiology, and end results (SEER) population-based study. 61
32309352 2020
38
Risk factor analysis for inaccurate pre-operative MRI staging in rectal cancer. 61
32216771 2020
39
[Total neoadjuvant therapy followed by watch and wait approach or organ preservation for MRI stratified low-risk rectal cancer: early result from a prospective, single arm trial]. 61
32192305 2020
40
Skip N2 Metastasis in Pulmonary Adenocarcinoma: Good Prognosis Similar to N1 Disease. 61
32245623 2020
41
Prognostic value of B-cell linker protein in colorectal cancer. 61
31980295 2020
42
Clinical and prognostic differences between surgically resected right-sided and left-sided colorectal cancer. 61
31612331 2020
43
Mucinous Adenocarcinoma as a High-risk Factor in Stage II Colorectal Cancer: A Propensity Score-matched Study from Japan. 61
32132070 2020
44
A study of radiomics parameters from dual-energy computed tomography images for lymph node metastasis evaluation in colorectal mucinous adenocarcinoma. 61
32176049 2020
45
A mucinous adenocarcinoma of the lip with elevated serum carcinoembryonic antigen levels: a case report. 61
31828452 2020
46
Rectum mucinous adenocarcinoma metastasis to bilateral breast in a male patient: A case report. 61
31541514 2020
47
Mucinous adenocarcinoma of the rectum with uninjured mucosa. 61
31081269 2020
48
Prognostic impact of preoperative immunonutritional status in rectal mucinous adenocarcinoma. 61
32067478 2020
49
Mucinous lung adenocarcinoma, particularly referring to EGFR-mutated mucinous adenocarcinoma. 61
31859434 2020
50
The Relationship of SUV Value in PET-CT with Tumor Differentiation and Tumor Markers in Gastric Cancer. 61
32158318 2020

Variations for Appendix Adenocarcinoma

Cosmic variations for Appendix Adenocarcinoma:

9
# Cosmic Mut ID Gene Symbol COSMIC Disease Classification
(Primary site, Site subtype, Primary histology, Histology subtype)
Mutation CDS Mutation AA GRCh38 Location Conf
1 COSM93760887 GNAS large intestine,appendix,carcinoma,adenocarcinoma c.2531G>A p.R844H 20:58909366-58909366 0

Expression for Appendix Adenocarcinoma

Search GEO for disease gene expression data for Appendix Adenocarcinoma.

Pathways for Appendix Adenocarcinoma

GO Terms for Appendix Adenocarcinoma

Biological processes related to Appendix Adenocarcinoma according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 response to isolation stress GO:0035900 8.96 HRAS KRAS
2 regulation of long-term neuronal synaptic plasticity GO:0048169 8.8 HRAS KRAS SYP

Sources for Appendix Adenocarcinoma

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 EFO
18 ExPASy
19 FMA
28 GO
29 GTR
30 HMDB
31 HPO
32 ICD10
33 ICD10 via Orphanet
34 ICD9CM
35 IUPHAR
36 KEGG
37 LifeMap
39 LOVD
41 MedGen
43 MeSH
44 MESH via Orphanet
45 MGI
48 NCI
49 NCIt
50 NDF-RT
53 NINDS
54 Novoseek
56 OMIM
57 OMIM via Orphanet
61 PubMed
63 QIAGEN
68 SNOMED-CT via HPO
69 TGDB
70 Tocris
71 UMLS
72 UMLS via Orphanet
Content
Loading form....